ClinConnect ClinConnect Logo
Search / Trial NCT06751706

Detection of Mycobacterium Tuberculosis in Blood of TB Patients and Their Contacts in Uganda

Launched by QUEEN MARY UNIVERSITY OF LONDON · Dec 27, 2024

Trial Information

Current as of June 26, 2025

Enrolling by invitation

Keywords

Tuberculosis Latent Tuberculosis Tb Tb Infection Tb Biomarker Blood Test For Tb

ClinConnect Summary

For many years, development of such a test was not considered realistic due to the paucibacillary nature of LTBI and uncertainty regarding the cellular location of Mtb bacilli in LTBI. However, the investigators and others have recently reported that Mtb DNA can be detected in the peripheral blood of latently infected TB contacts in both high- and low-burden settings. In our studies, which utilized digital polymerase chain reaction (dPCR) to detect Mtb DNA in peripheral blood mononuclear cell (PBMC) subsets of TB contacts in Ethiopia, signal was detected more frequently in extracts of CD34+...

Gender

ALL

Eligibility criteria

  • TB patients (Group A):
  • Inclusion Criteria:
  • Able and willing to give written informed consent to participate
  • Age ≥18 years
  • New diagnosis of smear-positive or Xpert-confirmed pulmonary TB
  • At least one asymptomatic adult household contact likely to fulfil TB contact eligibility criteria below
  • Exclusion criteria:
  • More than 7 days of anti-TB treatment taken
  • Confirmed or suspected pregnancy (female participants)
  • Existing medical condition which in the opinion of the investigator may adversely affect the participant's safety or ability to participate in the study.
  • Recent TB contacts (Group B):
  • Inclusion Criteria:
  • Able and willing to give written informed consent to participate
  • Age ≥18 years
  • Household contact with an index case of smear-positive pulmonary TB in Group A above.
  • Exclusion Criteria:
  • Clinical or radiological features of active TB
  • Current or previous anti-TB treatment
  • Confirmed or suspected pregnancy (female participants)
  • Existing medical condition which in the opinion of the investigator may adversely affect the participant's safety or ability to participate in the study.
  • Historical TB contacts (Group C):
  • Inclusion Criteria:
  • Able and willing to give written informed consent to participate
  • Age ≥18 years
  • Participant in previous TB household contact study
  • Exclusion Criteria:
  • Clinical or radiological features of active TB
  • Current or previous anti-TB treatment
  • Confirmed or suspected pregnancy (female participants)
  • Existing medical condition which in the opinion of the investigator may adversely affect the participant's safety or ability to participate in the study.

About Queen Mary University Of London

Queen Mary University of London is a prestigious research-intensive institution recognized for its commitment to advancing medical science and improving health outcomes. As a leading sponsor of clinical trials, the university harnesses its academic excellence and innovative research capabilities to explore groundbreaking treatments and therapies across various medical disciplines. With a focus on collaboration, the institution engages with a diverse network of clinicians, researchers, and industry partners to ensure rigorous study design, ethical conduct, and the translation of research findings into clinical practice. Queen Mary University of London is dedicated to contributing to the global body of knowledge in healthcare through high-quality clinical research that prioritizes patient safety and welfare.

Locations

Kampala, , Uganda

Patients applied

0 patients applied

Trial Officials

Adrian Martineau, PhD

Principal Investigator

Queen Mary University London

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported